Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation
Leverages Mindset’s Platform Technology for Efficient Delivery of CNS TherapeuticsTORONTO, June 29, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:...
Month: June 2022
InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19
Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMAProductive end-of-phase II meeting with FDA...
VectivBio Announces Closing of $54 Million Aggregate Financing
BASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel...
Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy
Neurona has initiated dosing of a first-ever regenerative human cell therapy candidate in a Phase 1/2 clinical trial for epilepsy...
Surface Oncology Appoints Carsten Brunn to Board of Directors
CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target...
Tilray Medical Expands Portfolio of Medical Cannabis Products in the UK
LEAMINGTON, Ontario, June 29, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a...
Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress
Overall response rate of 24%, and disease control rate of 73%, in heavily pre-treated patients with a median of 4...
PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch
Successfully delivered ketamine and KETABET™ (ketamine and betaine) via microneedle patch, unlocking the potential for desired dosage forms and pharmacokinetic...
BioAdaptives, Inc. Brings Top Revolutionary Formulas Together in Wellness Introductory Offer
Responding to Consumers, Management Offers Cost-Effective Combination With Enhanced Synergistic Benefits LAS VEGAS, NV , June 29, 2022 (GLOBE NEWSWIRE)...
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia
SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage...
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease
AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of action for patients with NTM...
MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases
MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases Financing led by Medicxi...
Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer
Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93%...
InvestmentPitch Media Video Discusses Reliq Health, a Rapidly Growing Global Telemedicine Company, Signs 6 New Contracts with Physician Practices, Home Health Agencies and Skilled Nursing Facilities, adding more than 3,500 Patients to its Platform
VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT) (OTCPink:RQHTF) (FSE:MHN2), a rapidly growing global...
Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following Cataract Surgery
Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following...
MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases
MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases Financing led by Medicxi...
89bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
SAN FRANCISCO, June 29, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the...
Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care
The BenchMark ULTRA PLUS tissue staining system, with optimised workflow, testing efficiency and environmentally sustainable features, enables pathologists to provide...
Santhera Updates on Ongoing NDA Submission for Vamorolone
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, June 29, 2022 – Santhera Pharmaceuticals (SIX: SANN) announces that the...
Sienna Senior Living Announces the Appointment of Dr. Gina Cody to Its Board of Directors
MARKHAM, Ontario, June 28, 2022 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) is pleased...